Sequence of the novel exon directly connected to the sequence of the 4th known exon that is marked by an arrow. The open reading frame is underlined and the start codon is shown in uppercase with Kozak consensus sequence shown in bold italic. The stop codon is shown in bold uppercase. doi:10.1371/journal.pone.0052425.gincubation of GST-CaM KMT fusion protein purified from bacteria with [3H-methyl] AdoMet resulted in labeling of GSTCaM KMT (see Figure S2).The Hexaconazole biological activity subcellular MedChemExpress (-)-Indolactam V localization of the CaM KMT ProteinsTo determine the subcellular localization of CaM KMT we subcloned it into pEGPF-N1 expression vector, which produce CaM KMT in-fusion with the C-terminal GFP tag and studied the cellular localization by confocal microscopy. Transfection of the CaM KMT-GFP into HeLa cells, showed both cytoplasmic and nuclear localization which was distinct from the diffused cellular localization of GFP control construct (Fig. 3A, B). We concluded that CaM KMT has nuclear and cytoplasmic distribution. We also determined the subcellular localization of the short CaM KMT variant, encoding a protein of 132 amino acids. This variant contains the same three 59 exons as CaM KMT and an additional 4th exon that lacks the methyltransferase domain. COS-7 cells were transfected with the GFP-CaM KMTsh construct andanalyzed by fluorescence microscopy. GFP-CaM KMTsh overexpression revealed a discrete localization near the nucleus, similar to the Golgi apparatus localization. To verify if CaM KMTsh was sublocalized to the Golgi, COS-7 transfected cells with the GFPCaM KMTsh were immunostained with the Golgi marker, anti58 k antibody. The fluorescent signals from the two proteins overlapped considerably, indicating that GFP-CaM KMT could localize to the Golgi (Fig. 3D). These results suggest that the short CaM KMT variant has a distinct subcellular localization from the full length variant. Using the affinity-purified polyclonal anti-CaM KMT antibody, we examined endogenous CaM KMT expression in different mouse tissues (Fig. 3C). Protein bands with the expected molecular masses of CaM KMT (36 kDa) were detected in most of the tissues examined, with the highest expression in the brain and muscle. The short variant could not be detected. These data support that CaM KMT is a ubiquitously expressed protein, including the high expression in the tissues affected in 2p21 deletion syndrome.Characterization of CaM KMTFigure 2. Analyses of the methylation status and relative amounts of CaM in lymphoblastoid cell lysates from a patient affected by the 2p21 deletion syndrome. (A) Phosphorimage of cell lysates from two 2p21 deletion syndrome patients and wild type individuals incubated in the presence of [3H-methyl] AdoMet with and without the addition of HsCaM KMT. (B) Phosphorimage as in panel (A) but after reduction in the level of CaM by treatment of the cell lysates with phenyl sepharose. Molecular mass markers in kDa are indicated between A and B. (C) Western blot performed with anti-CaM antibody to verify the presence of similar amounts of CaM in the 2p21 deletion syndrome patient and wild type individuals. (D) Western blot performed as in panel (C) on cell lysates after partial removal of CaM with phenyl sepharose. (E) Phosphorimage showing methylation of phenyl sepharose-bound CaM removed from 2p21 deletion syndrome patients cell lysates by the addition of HsCaM KMT and [3Hmethyl] 12926553 AdoMet. Molecular mass markers in kDa are indicated on the right. (F) Identification of the pr.Sequence of the novel exon directly connected to the sequence of the 4th known exon that is marked by an arrow. The open reading frame is underlined and the start codon is shown in uppercase with Kozak consensus sequence shown in bold italic. The stop codon is shown in bold uppercase. doi:10.1371/journal.pone.0052425.gincubation of GST-CaM KMT fusion protein purified from bacteria with [3H-methyl] AdoMet resulted in labeling of GSTCaM KMT (see Figure S2).The Subcellular Localization of the CaM KMT ProteinsTo determine the subcellular localization of CaM KMT we subcloned it into pEGPF-N1 expression vector, which produce CaM KMT in-fusion with the C-terminal GFP tag and studied the cellular localization by confocal microscopy. Transfection of the CaM KMT-GFP into HeLa cells, showed both cytoplasmic and nuclear localization which was distinct from the diffused cellular localization of GFP control construct (Fig. 3A, B). We concluded that CaM KMT has nuclear and cytoplasmic distribution. We also determined the subcellular localization of the short CaM KMT variant, encoding a protein of 132 amino acids. This variant contains the same three 59 exons as CaM KMT and an additional 4th exon that lacks the methyltransferase domain. COS-7 cells were transfected with the GFP-CaM KMTsh construct andanalyzed by fluorescence microscopy. GFP-CaM KMTsh overexpression revealed a discrete localization near the nucleus, similar to the Golgi apparatus localization. To verify if CaM KMTsh was sublocalized to the Golgi, COS-7 transfected cells with the GFPCaM KMTsh were immunostained with the Golgi marker, anti58 k antibody. The fluorescent signals from the two proteins overlapped considerably, indicating that GFP-CaM KMT could localize to the Golgi (Fig. 3D). These results suggest that the short CaM KMT variant has a distinct subcellular localization from the full length variant. Using the affinity-purified polyclonal anti-CaM KMT antibody, we examined endogenous CaM KMT expression in different mouse tissues (Fig. 3C). Protein bands with the expected molecular masses of CaM KMT (36 kDa) were detected in most of the tissues examined, with the highest expression in the brain and muscle. The short variant could not be detected. These data support that CaM KMT is a ubiquitously expressed protein, including the high expression in the tissues affected in 2p21 deletion syndrome.Characterization of CaM KMTFigure 2. Analyses of the methylation status and relative amounts of CaM in lymphoblastoid cell lysates from a patient affected by the 2p21 deletion syndrome. (A) Phosphorimage of cell lysates from two 2p21 deletion syndrome patients and wild type individuals incubated in the presence of [3H-methyl] AdoMet with and without the addition of HsCaM KMT. (B) Phosphorimage as in panel (A) but after reduction in the level of CaM by treatment of the cell lysates with phenyl sepharose. Molecular mass markers in kDa are indicated between A and B. (C) Western blot performed with anti-CaM antibody to verify the presence of similar amounts of CaM in the 2p21 deletion syndrome patient and wild type individuals. (D) Western blot performed as in panel (C) on cell lysates after partial removal of CaM with phenyl sepharose. (E) Phosphorimage showing methylation of phenyl sepharose-bound CaM removed from 2p21 deletion syndrome patients cell lysates by the addition of HsCaM KMT and [3Hmethyl] 12926553 AdoMet. Molecular mass markers in kDa are indicated on the right. (F) Identification of the pr.
